Concepedia

Kate E. Gilling

KE

Statistics

Publications

13

Citations

562

H-Index

12

Active since

2003

Affiliations

MerLion Pharma (Germany)(Current)

Charité - Universitätsmedizin Berlin

Technical University of Munich

Max Planck Institute of Psychiatry

Johannes Gutenberg University Mainz

Kate E. Gilling is an author at MerLion Pharma (Germany) specializing in neuropharmacology, neuroscience, and pharmacology.

Publications per year

2003–2020

13

Publications

13

Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor

B Eisensamer, Gerhard Rammes, Gerald Gimpl et al. · Molecular Psychiatry · 2003 · 123 citations

, , +14

Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors

Kate E. Gilling, Claudia Jatzke, Mirko Hechenberger et al. · Neuropharmacology · 2009 · 74 citations

, , +17

Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner

Gerhard Rammes, B Eisensamer, Uta Ferrari et al. · Molecular Psychiatry · 2004 · 67 citations

, , +17

Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer’s disease-like APPPS1 mice

Lisa Katharina Wagner, Kate E. Gilling, Eileen Schormann et al. · Acta Neuropathologica Communications · 2017 · 66 citations · Full text

, , +17

TCF11/Nrf1-Mediated Induction of Proteasome Expression Prevents Cytotoxicity by Rotenone

Franziska Sotzny, Eileen Schormann, Ina Kühlewindt et al. · Antioxidants and Redox Signaling · 2016 · 49 citations

, , +17

1–5 of 13